See what employees say it's like to work at Rubius Therapeutics . Care Access is part of Reify Health, a startup that was founded to reinvent clinical trials and has raised nearly half a billion dollars. 1 post Hes now founder of Sci.bio, a Boston-area biopharma recruitment and executive search firm thats worked with Rubius Therapeutics, , https://www.biopharma-reporter.com/Article/2018/07/27/Rubius-to-pay-8m-for-ex-Soliris-plant-with-troubled-past, Jul 27, 2018 Rubius has announced plans to acquire Alexions manufacturing facility facility and layoff 20% of its workforce in September last year, , https://mobile.twitter.com/maxgelman/with_replies. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. RTX-240 continued to be well tolerated with no treatment-related Grade 3/4 adverse events (AEs) and no dose-limiting toxicities. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. The highest-paying job at Rubius Therapeutics is a Director with a salary of $291,416 per year. envie um e-mail para Cell conjugation creates a covalent link between the cell surface and the molecule of interest. Additional leadership changes include the departures of Pepe Carmona, chief financial officer, and Maiken Keson-Brookes, chief legal officer and corporate secretary. These measures include: The Company will maintain its robust technical development and preclinical oncology and autoimmunity research capabilities to advance the new platform and related preclinical programs. Si vous continuez voir ce Onze What is the highest salary at Rubius Therapeutics? After an earlier failure, this one is kaput. Astellas Pharma will buy New Jersey biotech Iveric Bio for $40 per share in cash, the companies said Sunday night, setting up the Tokyo drugmaker for a potential showdown with Apellis Pharmaceuticals in geographic atrophy. AACR22: Rubius touts new data for lead program, but shares routed as investors flee. Rubius is behind genetically engineered red blood cells that are meant to fight cancer and other diseases. Topics covered: Gene replacement therapy, gene editing, engineered cell therapy, manufacturing, pricing, reimbursement and much more. By March 2020, the stock dipped below $4. Rubius shares soared again in March 2021 when the company announced early clinical data in cancer patients that it claimed offered a proof of concept for its technology. Shares were worth about 30 cents in early trading Thursday, giving the company a market value of less than $30 million. Rubius Therapeutics Financials. Another Third Rock biotech, Rheos Medicines, also shut down late last year, according to Endpoints News. Unlock this article along with other benefits by subscribing to one of our paid plans. Rubius will halt Phase 1 trials of cancer drug candidates RTX-240 and RTX-224 and instead invest in a newer method of making its medicines thats meant to lead to more effective products. However, its initial lead program, for a rare metabolic disorder, was delayed and eventually scrapped in 2020 after trial results were uninterpretable.. Based on these early findings, we firmly believe in the potential of Red Cell Therapeutics for the treatment of cancer and autoimmunity. The highest-paying job at Rubius Therapeutics is a Director with a salary of $291,416 per year. Rubius went public in 2018 with a $277 million IPO. Please note this link is one-time use only and is valid for only 24 hours. Please help us protect Glassdoor by verifying that you're a As always, we welcome your feedback on the format and content of the report. Can You Get Laid Off While On Maternity Leave, Can Laid Off Union Workers Collect Unemployment, How Long Does Insurance Last After Being Laid Off. message, contactez-nous l'adresse Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Possibilities include a sale of all or part of the company. Si continas viendo este mensaje, The plan was to. As a result, we have decided to discontinue our ongoing clinical trials of RTX-240 and RTX-224 for the treatment of advanced solid tumors and restructure the organization to support advancing drug candidates based on the next generation platform. Net income (FY, 2022)($179.7M) Cash (FY, 2022)$14.9M EBIT (FY, 2022)($178.4M) Enterprise value This press release contains certain statements that constitute forward-looking statements within the meaning of applicable laws and regulations and constitute forward-looking information within the meaning of applicable securities laws, including, without limitation, statements regarding our plans to initiated a process to explore a range of strategic alternatives and our plans to reduce our operations and execute certain leadership changes. Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases. Rubius has recently generated new non-human primate data with the next generation cell conjugation RED PLATFORM, demonstrating longer circulation time than observed with the first generation platform and pronounced pharmacodynamic effects as shown by increased levels of interferon gamma, a cytokine critical to both innate and adaptive immunity. . In a second round of layoffs, Rubius Therapeutics cut 82% of its workforce and said it is reviewing its options. Sio Gene Therapies and Otonomyboth announced plans in December to shutter operations. Rubius Therapeutics employees rate the overall compensation and benefits package 4.2/5 stars. scusiamo se questo pu causarti degli inconvenienti. Phase 1 Clinical Trial of RTX-240 + Pembrolizumab in Advanced Solid Tumors. / COURTESY RUBIUS THERAPEUTICS SMITHFIELD - Rubius Therapeutics plans to lay off 75% of its workforce, including about 70 of its 101 employees in Rhode Island, and is "exploring the sale of its manufacturing facility" in the town, the biotech company announced on Tuesday morning. In addition to the layoffs, Rubius is . Rubius Therapeutics, Inc. 2023. With more than 80 patients dosed across three clinical trials to date, Rubius Therapeutics has demonstrated that engineered red blood cells can be manufactured at scale, safely administered and activate a patients immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors, said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics. Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de Wenn Welcome back to Endpoints Weekly, your review of the weeks top biopharma headlines. You almost have to feel sorry for the R&D groups that try to challenge Vertexs $10 billion cystic fibrosis franchise. Dannielle Appelhans to Become President and Chief Executive Officer, Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors. Investor and Media ContactLori Murray, Chief Corporate Affairs Officer lori.murray@rubiustx.com, Rubius Therapeutics Announces Strategic Update. 1 post Hes now founder of Sci.bio, a Boston-area biopharma recruitment and executive search firm thats worked with Rubius Therapeutics , , With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image. Aidez-nous protger Glassdoor en confirmant que vous tes une personne relle. Alnylam Pharmaceuticals unveiled the first evidence that its RNA interference technology can dramatically reduce levels of proteins linked to Alzheimers disease, an early but intriguing result that could prompt new approaches to treating the memory-robbing condition. With our deep scientific know-how and dedicated team, we are focused on making our vision a realitycreating life-changing cellular therapies for patients with cancer and autoimmune diseases. LSC makes impactful grants to community . Topics covered: Drug commercialization, pharma salesforces, generic and biosimilar competition, drug advertising and much more. We caution that trading in our securities is highly speculative and poses substantial risks. to let us know you're having trouble. I would like to express my sincere gratitude to the patients who participated in our clinical trials, the investigators who partnered with us in this endeavor and our employees for their immense dedication and contributions that have brought us to where we are today., Next Generation Red Blood Cell-Based Conjugation Platform Overview. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. The past four years have been a roller coaster for investors in Rubius, which burst onto the biotech scene with the intriguing goal of turning engineered red blood cells into medicines. Overdose hot spot to get R.I.s 1st safe injection Bridging gaps to help patients get proper care, Bryant to host inaugural health care summit, Blue Cross to open new store in Narragansett. Seven patients were dosed at 5e10 Q3W with one anal cancer patient experiencing stable disease for 5 months before disease progression. At least 23 companies have announced layoffs so far this year, and the list keeps growing. On Wednesday, the Cambridge, MA-based biotech and its partner Regeneron announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP. When he formally steps down as CEO on Nov. 15, Cagnoni will become an executive partner at Flagship. Our proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and off-the-shelf . This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectation for the restructuring plan described in this release, including associated costs, cost savings and timing, as well as our beliefs about the next generation red blood cell platform, including that it will potentially improve upon the existing benefits of the RED PLATFORM, and its potential for greater efficacy and enhanced versatility. Any forward-looking statements contained in this release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Cambridge, Massachusetts-based biotech, which was worth nearly $2 billion when it went public in 2018, announced the moves on Tuesday in a bid to cut costs. Founder Bryan Manning, who has a rare disease himself, A drug should never fail because it cannot find the patients it can help the most and Sponsors should not pay for patients they cant help. Topics covered: Gene replacement therapy, gene editing, engineered cell therapy, manufacturing, pricing, reimbursement and much more. Seven patients have been dosed across two dose cohorts in the Phase 1 clinical trial evaluating RTX-224 in select advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. Founded out of Flagship Pioneering in 2013, the company went public in 2018 in what was. Topics covered: startup launches, funding, IPOs and much more. Rubius Therapeutics kicks off $155M renovation of former , Rubius touts new data for lead program, but shares routed as , Working at Rubius Therapeutics | Glassdoor, Stay alive': Wave of layoffs crashes into biotech startup , Rubius to pay $8m for ex-Soliris plant with troubled past, Tweets with replies by Max Gelman (@MaxGelman) / Twitter, With data looming, Rubius Therapeutics seeks to shed its , Rubius Therapeutics Reports Third Quarter 2021 Financial, Rubius Drops Rare Diseases, Turns to Cancer and Xconomy, Can You Be Laid Off While On Medical Leave, Can A Company Find Out If You Were Laid Off, Can You Say You Were Laid Off Instead Of Fired, Can You Go On Disability After Being Laid Off, Can You Be Laid Off While On Short-Term Disability. Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines. deliver a higher effective dose by enabling a longer circulation time and/or administering a higher cell dose; be more versatile, enabling the conjugation of different payloads, immunomodulatory agents, small molecules and proteins on the cell for enhanced potency; and, reduce the cost of goods manufacturing by utilizing blood-banked RBCs versus biologically engineering and differentiating early progenitor cells into reticulocytes that express proteins. Many top-selling products will lose patent protection by the end of the decade, putting pressure on companies to replace lost revenue with new medicines. Red , Rubius to pay $8m for ex-Soliris plant with troubled past, Stay alive': Wave of layoffs crashes into biotech startup , With data looming, Rubius Therapeutics seeks to shed its , Rubius Therapeutics Reports Third Quarter 2021 Financial, Rubius Drops Rare Diseases, Turns to Cancer and Xconomy, Can You Be Laid Off While On Medical Leave, Can A Company Find Out If You Were Laid Off, Can You Say You Were Laid Off Instead Of Fired, Can You Go On Disability After Being Laid Off, Can You Be Laid Off While On Short-Term Disability. naar In late July 2018, Rubius shares briefly traded as high as $27 apiece, but then began a slow decline as the company encountered delays in producing study data and later switched its research focus. The biotech is also exploring selling a manufacturing facility in Rhode Island that it bought in 2018 with plans to invest nearly $100 million. We'll e-mail you a link to set a new password. Current Endpoints readerscan visit their reader profileto add Endpoints Weekly. . Clinical Enrollments novel approach reduces randomization timelines, and screen fail rates by introducing clinical trials to patients while they are researching their disease and qualifies them with both online and US-based phone screening programs. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Save my name, email, and website in this browser for the next time I comment. The company next turned its focus to cancer medicines, and early clinical results for its top two prospects were expected later this year. Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. It can be challenging to witness a talented team dedicated to discovering new medicines fall short of their ambitious goals in a demanding market. The real reason Europes medicines industry is dying, Congress Considers Paying Developers of New Antibiotics, Sangamo to lay off 120 as it pares pipeline, A startup taking a different approach to Alzheimers gets fresh funds, Lilly backing, Orbital raises $270 million in biotechs largest Series A round this year. Founded by Flagship Pioneering in 2014, the company launched a large initial public offering in mid-2018, and Cagnoni became one of the most well-compensated CEOs in the biotech industry. Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. Ambys Medicines, which launched in 2018 to develop cell therapies for liver disease, wound down operations in late 2022, according to the website of one of its backers, Third Rock Ventures. The layoffs announced are expected to primarily hit clinical development and manufacturing teams and some administrative members. Eli Lilly said new data from a Phase III trial showed that tirzepatide helped patients who are overweight or obese and have type 2 diabetes lose 15.7% of their body weight. Just shoot me an email. It found that a higher dose of tirzepatide helped patients lose 15.7% of their weight or 15.6 kg over 72 weeks, and a lower dose spurred weight reduction of 13.4%, or 13.5 kg. Seeker Biologics, a Boston-based biotech startup formed out of 5AM Ventures to make new biologics, has shut down. Four patients had stable disease of greater than 12 weeks with one colorectal cancer patient remaining on study with stable disease of greater than 4 months. In 2018, Alexion offered $855 million in cash to acquire Wilson Therapeutics for the candidate, designed to treat Wilson disease a rare condition where patients cant remove copper from the body, resulting in excessive amounts of copper accumulating in the liver, brain and eyes. real person. Can I Be Laid Off While On Workers Compensation? If the plan is approved, Rubius will pay down liabilities and return to shareholders remaining cash, which had totaled more than $100 million at the end of September but was substantially reduced by the companys prepayment of $76 million worth of loan obligations in October. Sie weiterhin diese Meldung erhalten, informieren Sie uns darber bitte per E-Mail The company was formed by biotech startup creator Flagship Pioneering with an ambitious plan to re-engineer blood cells to fight cancer and autoimmune diseases. Tougher funding conditions have forced biotechs to retrench over the past year by laying off staff or reducing research. Ci The Company was named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named2022Best Places to Work in Rhode Islandby Providence Business News. Seeker set out to make new medicines for autoimmune, allergic and inflammatory diseases and had secured a Series A financing, according to job postings and profile descriptions on LinkedIn. Topics covered: startup launches, funding, IPOs and much more. Want this in your inbox every Saturday morning? Rubius Therapeutics Profile and History . Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Phase 1 Clinical Trial of Monotherapy RTX-240. Aydanos a proteger Glassdoor y demustranos que eres una persona real. Forward-Looking Statements The Flagship Pioneering spinout (Nasdaq: RUBY) said late Wednesday that it was laying off 82% of its workforce and would begin. In parallel, the Company has advanced a next generation Red Cell Therapeutic, RTX-250, an antigen-specific therapy that is designed to activate dendritic cells. Executives took advantage of the bump to offer another round of shares at $29 a piece. All Rights Reserved. I can almost guarantee that you will read something in this issue that you overlooked the past few days. Higher ed in R.I. grapples with the use of ChatGPT, Epilepsy Foundation New England receives $1.4M Public Health AmeriCorps grant, Kicked off Medicaid: Millions at risk as states trim rolls, Commission clears way for nursing and health science facility at PC, Wrights Dairy Farms ice cream shop opening in Providence this weekend, 2023 Leaders and Achievers Awards Program, Judge rules against Google, allows antitrust case to proceed, PBN announces 2023 Best Places to Work honorees. Follow PBN for the latest news, insider access and more. Summary financials. Want to share this story? Wrights Dairy Farms ice cream shop opening in Providence Providence East Side colonial-style home sells for $1.3M, Businesses can play key role in boosting workforce housing. Register today to celebrate our Business Women Honorees. In 2019, the company began to encounter delays in producing study data and later switched its research focus. Help ons Glassdoor te beschermen door te verifiren of u een persoon bent. Rubius is one of at least five biotechs that have announced plans to shut down in the past four months. All Rights Reserved. questo messaggio, invia un'email all'indirizzo Phase 1 Clinical Trial of RTX-224 in Select Advanced Solid Tumors. The combination of RTX-240 with pembrolizumab continued to be well tolerated with no treatment or investigator-identified immune-related Grade 3/4 AEs and no dose-limiting toxicities. Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. Read More RUBY Stock News Headlines April 20, 2023 | americanbankingnews.com Our proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell. One patient with renal cell carcinoma remains on study with stable disease for more than one year after developing progressive disease on prior treatment with nivolumab. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Any such risks and uncertainties could materially and adversely affect our results of operations and cash flows and the amount of time we can meet our operational and capital needs. Rubius Apr 18, 2023 - Sr Director, Manufacturing Operations in Boston, MA Recommend CEO Approval Business Outlook Pros Great team to work with Cons Products are questionable and leadership team does not seem to care Be the first to find this review helpful Helpful Share Join the Rubius Therapeutics team See Our Latest Jobs 5.0 Topics covered: Gene replacement therapy, gene editing, engineered cell therapy, manufacturing, pricing, reimbursement and much more. In . RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners. Yesterday, AbbVie R&D chief Tom Hudson shrugged off a major setback for the company, noting that its mid-stage CF triple had failed an interim review and we are discontinuing our cystic fibrosis program.. Save my name, email, and website in this browser for the next time I comment. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts. Mar 9, 2021 With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image. Rubius Therapeutics Inc. is in the final days of its existence. Bitte helfen Sie uns, Glassdoor zu schtzen, indem Sie besttigen, dass Sie Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases. CEO Pablo Cagnoni will step down Nov. 15, along with the biotech's chief financial officer and top lawyer. That is why our pricing model is exclusively ICF and randomization based.. They are a biopharmaceutical company that creates red blood cells and transforms them into cellular medicines. Following careful review of recent technical progress in an alternative format for making Red Cell Therapeutics, we believe that this process has the potential for substantive improvements over our existing platform, and, therefore, continued investment in our two current clinical candidates is no longer justified. Rubius Therapeutics kicks off $155M renovation of former , Working at Rubius Therapeutics | Glassdoor, Rubius touts new data for lead program, but shares routed as , Flagship woos another Big Pharma BD exec to biotech. Rubius Therapeutics kicks off $155M renovation of former https://www.fiercepharma.com/manufacturing/rubius-therapeutics-kicks-off-155m-renovation-former-alexion-plant-r-i In March, Athenex announced that it was planning to layoff an undisclosed number of its employees, which was pegged at a total of 652 full-time workers as of Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines. Rubius is one of at least five biotechs that have announced plans to shut down in the past four months. ein Mensch und keine Maschine sind. And in January, Goldfinch Bio confirmed it was closing,selling off the rights to its medicines to Karuna Therapeutics earlier this month. New biotechs continue to emerge despite a challenging market environment that has persisted in 2023, forcing venture firms to build their drug startups more cautiously. It is the latest in a series of setbacks Rubius has suffered since raising $241 million in an initial public offering in 2018. Its shares soared in March 2021 when the company claimed early clinical data offered proof of concept for its technology. Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform, Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023, Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors, Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT. Get the free daily newsletter read by industry experts. enva un correo electrnico a Si continas recibiendo este mensaje, infrmanos del problema They are a biopharmaceutical company that creates red blood cells and transforms them into cellular medicines. Boston was founded in 2016 to provide a platform for companies and their employees to make a difference. The company, which makes engineered red cells, was raking in ample cash and had enjoyed a $1.8 billion market valuation registered at the IPO. Salaries, reviews, and more - all posted by employees working at Rubius Therapeutics . Even if its a quite capable market brawler like AbbVie. 230 Employees . With the first generation Red Cell Therapeutics, Rubius demonstrated that engineered red blood cells could be manufactured at scale, safely administered and activate a patients immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Additional information on the leadership and board changes, and the Companys plan for strategic alternatives, can be found in Rubius current report on Form 8-K being filed with the U.S. Securities and Exchange Commission on or about the date hereof. verdade. ALXN1840, or bis-choline tetrathiomolybdate, had in turn come to Alexion from a buyout. SURMOUNT-2 is the second late-stage trial testing the drug as a treatment for obesity or overweight, but this study focused on patients who also have type 2 diabetes. Aydanos a proteger Glassdoor verificando que eres una persona real. Get the free daily newsletter read by industry experts. Topics covered: Drug commercialization, pharma salesforces, generic and biosimilar competition, drug advertising and much more. The Company was named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named2022Best Places to Work in Rhode Islandby Providence Business News. Se continui a visualizzare Kicked off Medicaid: Millions at risk as states trim Commission clears way for nursing and health science facility Providence accepting applications for mayoral fellows, Politics of bank regulation never about making banks safer. CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform. an. Rubius Therapeutics | Red Cell TherapeuticsTM | Home Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them , https://www.globenewswire.com/news-release/2021/11/08/2329769/0/en/Rubius-Therapeutics-Reports-Third-Quarter-2021-Financial-Results-and-Provides-Business-Update.html, Nov 8, 2021 Along with this leadership change, chief medical officer Christina Coughlin, M.D., Ph.D., will be leaving Rubius Therapeutics to pursue another , https://xconomy.com/boston/2020/03/12/rubius-drops-rare-diseases-turns-to-cancer-and-autoimmune-disorders/, Mar 12, 2020 Rubius Therapeutics is dropping its lead drug candidateand its focus on rare diseasesin favor of earlier-stage cell therapies that it has .
© 2023 Lembecker TV 1974 e.V.